Ali Rajabpour Sanati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Rajabpour Sanati has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Ali Mohammad Pourbagher-Shahri
Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications Fariba Nakhaei
2 shared publications- Fariborz Ghaffarpasand
Research Center for Neuromodulation and Pain, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications Hamidreza Riasi
2 shared publications- Mahsa Mayeli
Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA
2 shared publications Majid Zare Bidaki
2 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (8) , e72914
Diagnostic Performance of the AlzoSure Predict Assay and Its Association With Alzheimer's Disease Biomarkers and Imaging Findings
Background: Early diagnosis of Alzheimer's disease (AD) is critical for improving patient outcomes. The laboratory‐developed blood test of AlzoSure measures the unfolded conformational variant of p53 (U‐p53AZ) in plasma and has shown promise as a screening tool for AD risk. We aimed to evaluate the association between U‐p53AZ with established cerebrospinal fluid (CSF) and neuroimaging measures, and to determine its diagnostic performance in distinguishing cognitively normal (CN) individuals from those with mild cognitive impairment (MCI). Methods: Participants included CN and MCI individuals aged 55–90 years with complete baseline and 24‐month follow‐up assessments. Associations between U‐p53AZ, CSF biomarkers, standardized uptake value ratio (SUVR) of glucose measured by fluorodeoxyglucose positron emission tomography (FDG‐PET), and cognition were examined with multivariable regression models adjusted for age, sex, and APOE ε4 status. Diagnostic performance was assessed with receiver operating characteristic (ROC) analysis. Results: At baseline, no significant group differences were observed in plasma U‐p53AZ, FDG SUVR, or CSF biomarkers between CN and MCI. Longitudinally, FDG SUVR significantly declined in MCI ( p = 0.040), while CSF t‐tau and p‐tau181 increased in both groups (all p < 0.05). Higher U‐p53AZ levels were independently associated with elevated CSF t‐tau ( β = 0.38; p = 0.033) and p‐tau181 ( β = 0.37; p = 0.033) at baseline, and these associations persisted at follow‐up ( β range 0.43–0.48; all p < 0.02). No significant associations were found with FDG SUVR or cognitive scores. The discriminative ability of U‐p53AZ to distinguish CN from MCI was modest (AUC = 0.617, 95% CI 0.518–0.716). Conclusion: AlzoSure measurements are significantly associated with CSF tau values but demonstrate limited utility in differentiating CN from MCI. Although promising as a marker of tau‐related neurodegeneration, AlzoSure has a modest diagnostic performance as a stand‐alone assessment.
- 31 July 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (8) , e72914
Open AccessDiagnostic Performance of the AlzoSure Predict Assay and Its Association With Alzheimer's Disease Biomarkers and Imaging Findings
Background: Early diagnosis of Alzheimer's disease (AD) is critical for improving patient outcomes. The laboratory‐developed blood test of AlzoSure measures the unfolded conformational variant of p53 (U‐p53AZ) in plasma and has shown promise as a screening tool for AD risk. We aimed to evaluate the association between U‐p53AZ with established cerebrospinal fluid (CSF) and neuroimaging measures, and to determine its diagnostic performance in distinguishing cognitively normal (CN) individuals from those with mild cognitive impairment (MCI). Methods: Participants included CN and MCI individuals aged 55–90 years with complete baseline and 24‐month follow‐up assessments. Associations between U‐p53AZ, CSF biomarkers, standardized uptake value ratio (SUVR) of glucose measured by fluorodeoxyglucose positron emission tomography (FDG‐PET), and cognition were examined with multivariable regression models adjusted for age, sex, and APOE ε4 status. Diagnostic performance was assessed with receiver operating characteristic (ROC) analysis. Results: At baseline, no significant group differences were observed in plasma U‐p53AZ, FDG SUVR, or CSF biomarkers between CN and MCI. Longitudinally, FDG SUVR significantly declined in MCI ( p = 0.040), while CSF t‐tau and p‐tau181 increased in both groups (all p < 0.05). Higher U‐p53AZ levels were independently associated with elevated CSF t‐tau ( β = 0.38; p = 0.033) and p‐tau181 ( β = 0.37; p = 0.033) at baseline, and these associations persisted at follow‐up ( β range 0.43–0.48; all p < 0.02). No significant associations were found with FDG SUVR or cognitive scores. The discriminative ability of U‐p53AZ to distinguish CN from MCI was modest (AUC = 0.617, 95% CI 0.518–0.716). Conclusion: AlzoSure measurements are significantly associated with CSF tau values but demonstrate limited utility in differentiating CN from MCI. Although promising as a marker of tau‐related neurodegeneration, AlzoSure has a modest diagnostic performance as a stand‐alone assessment.
- 18 June 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (6) , 1-15
Amino acid patterns predict white matter integrity measures in the brain in patients across the Alzheimer’s disease continuum
Alzheimer’s disease (AD), the leading cause of dementia, poses a growing global health challenge due to its rising prevalence and socioeconomic impact. Investigating metabolic alterations associated with white matter integrity (WMI) could provide critical insights into AD pathogenesis and identify potential therapeutic targets. This cross-sectional study explored the associations between amino acid (AA) profiles, assessed via ultra-high-performance liquid chromatography (UHPLC), and WMI metrics derived from diffusion tensor imaging (DTI) in individuals across the AD continuum. A total of 176 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included and grouped into cognitively normal (CN) individuals (n = 54), patients with mild cognitive impairment (MCI, n = 88), and AD patients (n = 34). WMI was evaluated using DTI-derived metrics, including fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD). AA profiling was conducted using an appropriate panel. Regression analyses, adjusted for age, gender, and education, was used to identify significant associations between AA levels and WMI. Distinct AA alterations were associated with white matter microstructural integrity across study groups. In CN individuals, higher levels of arginine, glycine, and threonine correlated with decreased FA and increased MD, indicating reduced white matter integrity. Conversely, in AD patients, aspartate, glutamate, and histidine exhibited opposite associations, showing positive correlations with FA and negative correlations with MD, suggesting potential neuroprotective or compensatory mechanisms. These findings underscore the associations between AA patterns and white matter integrity and their potential role as AD progression markers. Further investigations into these AA metabolism pathways may identify novel biomarkers for early diagnosis and targets for therapeutic interventions.
- 18 June 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (6) , 1-15
Amino acid patterns predict white matter integrity measures in the brain in patients across the Alzheimer’s disease continuum
Alzheimer’s disease (AD), the leading cause of dementia, poses a growing global health challenge due to its rising prevalence and socioeconomic impact. Investigating metabolic alterations associated with white matter integrity (WMI) could provide critical insights into AD pathogenesis and identify potential therapeutic targets. This cross-sectional study explored the associations between amino acid (AA) profiles, assessed via ultra-high-performance liquid chromatography (UHPLC), and WMI metrics derived from diffusion tensor imaging (DTI) in individuals across the AD continuum. A total of 176 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included and grouped into cognitively normal (CN) individuals (n = 54), patients with mild cognitive impairment (MCI, n = 88), and AD patients (n = 34). WMI was evaluated using DTI-derived metrics, including fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD). AA profiling was conducted using an appropriate panel. Regression analyses, adjusted for age, gender, and education, was used to identify significant associations between AA levels and WMI. Distinct AA alterations were associated with white matter microstructural integrity across study groups. In CN individuals, higher levels of arginine, glycine, and threonine correlated with decreased FA and increased MD, indicating reduced white matter integrity. Conversely, in AD patients, aspartate, glutamate, and histidine exhibited opposite associations, showing positive correlations with FA and negative correlations with MD, suggesting potential neuroprotective or compensatory mechanisms. These findings underscore the associations between AA patterns and white matter integrity and their potential role as AD progression markers. Further investigations into these AA metabolism pathways may identify novel biomarkers for early diagnosis and targets for therapeutic interventions.
- 6 July 2023
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 114, 146-150
Effect of Dexmedotomdine hydrochloride (Percedex®) on functional outcome of patients with moderate and severe traumatic brain injury
- 6 July 2023
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 114, 146-150
Effect of Dexmedotomdine hydrochloride (Percedex®) on functional outcome of patients with moderate and severe traumatic brain injury
- 1 July 2023
- Published by IATED Academy in EDULEARN Proceedings
- Vol. 1, 2686
DEVELOPING AN AI-BASED PLATFORM FOR PERSONALIZED LEARNING IN NEUROLOGY EDUCATION FOR MEDICAL STUDENTS
- 1 July 2023
- Published by IATED Academy in EDULEARN Proceedings
- Vol. 1, 2686
DEVELOPING AN AI-BASED PLATFORM FOR PERSONALIZED LEARNING IN NEUROLOGY EDUCATION FOR MEDICAL STUDENTS
- 1 July 2023
- Published by IATED Academy in EDULEARN Proceedings
- Vol. 1, 2673
ANALYZING THE IMPACT OF AI-ASSISTED DIAGNOSIS ON MEDICAL STUDENTS' UNDERSTANDING OF NEUROLOGICAL DISORDERS
- 1 July 2023
- Published by IATED Academy in EDULEARN Proceedings
- Vol. 1, 2673
ANALYZING THE IMPACT OF AI-ASSISTED DIAGNOSIS ON MEDICAL STUDENTS' UNDERSTANDING OF NEUROLOGICAL DISORDERS
- 1 March 2023
- Published by Taylor & Francis in Epigenomics
- Vol. 15 (5) , 271-281
Modifications Of Mirnas In Intervertebral Disc Degeneration: A Key To The Future Development Of Genetic-Based Therapies
Intervertebral disc degeneration (IDD) is the main cause of low back pain, which is a healthcare concern associated with high social and economic burden. The current medical and surgical therapies ...
- 1 March 2023
- Published by Taylor & Francis in Epigenomics
- Vol. 15 (5) , 271-281
Modifications Of Mirnas In Intervertebral Disc Degeneration: A Key To The Future Development Of Genetic-Based Therapies
Intervertebral disc degeneration (IDD) is the main cause of low back pain, which is a healthcare concern associated with high social and economic burden. The current medical and surgical therapies ...
- Open Access
- 6 May 2020
- Published by DoNotEdit in Journal of Surgery and Trauma
- Vol. 8 (1) , 8-15
Comparison of two different doses of citicoline in patients with traumatic brain injury
Introduction: The ever-increasing and common occurrence of head traumas highlight the importance of adopting therapeutic measures for the reduction of the associated morbidity and mortality. Citicoline, as a safe medicine with positive effects on improving traumatic injuries, has been proven to be useful in various studies. However, there are still no data on the specific standard method and dosage of citicoline for the treatment of patients with traumatic head injuries. Regarding this, the present study was performed to determine the effective therapeutic dosage of citicoline and its impact on patients with traumatic head injuries. Methods: This double-blind clinical trial was performed on 30 patients with traumatic concussion (a Glasgow coma scale [GCS] of ≤8) admitted to the intensive care unit and neurosurgery department. The patients were randomly divided into three groups of A (control), B (citicoline with a dosage of 0.5 g/twice a day), and C (citicoline with a dosage of 1.5 g/twice a day). The GCS, degree of muscle strength, Glasgow outcome score (GOS), contusion volume, and cerebral edema (based on brain CT scans) were calculated at specific times and intervals. In addition, the patients' dependency on a ventilator and their length of ICU stay were registered. Results: Mean GCS on the first day of stay, GCS changes on the third and fourth days of stay, first and seventh days of stay, seventh and fourteenth days of stay, and first and fourteenth days of stay in the three study groups showed the significant statistical difference (P<0.05). Significant statistical differences were seen between the GOS of the 30th day of stay in the three study groups (P<0.05). The contusion volume difference was only significant between the first and seventh days of stay in groups A and C (P<0.05). No significant difference was observed in the mean length of stay in ICU and duration of dependency on a ventilator in the three study groups (P<0.05). The mean degree of muscle strength was only significantly different on the first day of stay between groups B and C (P=0.008). Conclusions: In contrary to similar studies, the results of the current study revealed that citicoline had no positive effect on patient healing. This result may be due to the small sample size and the inconsistent first-day GCSs of the patients in all three groups. Therefore, given the confirmation of the effectiveness of citicoline even at higher dosages in other studies in future studies, it is recommended to use populations with a larger number of patients.
- 6 May 2020
- Published by DoNotEdit in Journal of Surgery and Trauma
- Vol. 8 (1) , 8-15
Open AccessComparison of two different doses of citicoline in patients with traumatic brain injury
Introduction: The ever-increasing and common occurrence of head traumas highlight the importance of adopting therapeutic measures for the reduction of the associated morbidity and mortality. Citicoline, as a safe medicine with positive effects on improving traumatic injuries, has been proven to be useful in various studies. However, there are still no data on the specific standard method and dosage of citicoline for the treatment of patients with traumatic head injuries. Regarding this, the present study was performed to determine the effective therapeutic dosage of citicoline and its impact on patients with traumatic head injuries. Methods: This double-blind clinical trial was performed on 30 patients with traumatic concussion (a Glasgow coma scale [GCS] of ≤8) admitted to the intensive care unit and neurosurgery department. The patients were randomly divided into three groups of A (control), B (citicoline with a dosage of 0.5 g/twice a day), and C (citicoline with a dosage of 1.5 g/twice a day). The GCS, degree of muscle strength, Glasgow outcome score (GOS), contusion volume, and cerebral edema (based on brain CT scans) were calculated at specific times and intervals. In addition, the patients' dependency on a ventilator and their length of ICU stay were registered. Results: Mean GCS on the first day of stay, GCS changes on the third and fourth days of stay, first and seventh days of stay, seventh and fourteenth days of stay, and first and fourteenth days of stay in the three study groups showed the significant statistical difference (P<0.05). Significant statistical differences were seen between the GOS of the 30th day of stay in the three study groups (P<0.05). The contusion volume difference was only significant between the first and seventh days of stay in groups A and C (P<0.05). No significant difference was observed in the mean length of stay in ICU and duration of dependency on a ventilator in the three study groups (P<0.05). The mean degree of muscle strength was only significantly different on the first day of stay between groups B and C (P=0.008). Conclusions: In contrary to similar studies, the results of the current study revealed that citicoline had no positive effect on patient healing. This result may be due to the small sample size and the inconsistent first-day GCSs of the patients in all three groups. Therefore, given the confirmation of the effectiveness of citicoline even at higher dosages in other studies in future studies, it is recommended to use populations with a larger number of patients.
- Open Access
- 30 November 2019
- Published by DoNotEdit in Journal of Surgery and Trauma
- Vol. 7 (3) , 109-112
A lactating boy presenting with pituitary adenoma: A case report
Pituitary adenoma which is one of the most common brain lesions accounts for about 10%-15% of all central nervous system (CNS) tumors. The most common type of pituitary adenoma is prolactinoma which is responsible for 45% of pituitary tumors and considered the leading cause of hypogonadism and infertility. Prolactinomas are ...
- 30 November 2019
- Published by DoNotEdit in Journal of Surgery and Trauma
- Vol. 7 (3) , 109-112
Open AccessA lactating boy presenting with pituitary adenoma: A case report
Pituitary adenoma which is one of the most common brain lesions accounts for about 10%-15% of all central nervous system (CNS) tumors. The most common type of pituitary adenoma is prolactinoma which is responsible for 45% of pituitary tumors and considered the leading cause of hypogonadism and infertility. Prolactinomas are ...
- Open Access
- 1 October 2018
- Vol. 2 (4) , e45
Pain Management in the Emergency Department: a Review Article on Options and Methods
Context: The aim of this review is to recognizing different methods of analgesia for emergency medicine physicians (EMPs) allows them to have various pain relief methods to reduce pain and to be able to use it according to the patient's condition and to improve the quality of their services. Evidence acquisition: In this review article, the search engines and scientific databases of Google Scholar, Science Direct, PubMed, Medline, Scopus, and Cochrane for emergency pain management methods were reviewed. Among the findings, high quality articles were eventually selected from 2000 to 2018, and after reviewing them, we have conducted a comprehensive comparison of the usual methods of pain control in the emergency department (ED). Results: For better understanding, the results are reported in to separate subheadings including "Parenteral agents" and "Regional blocks". Non-opioids analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are commonly used in the treatment of acute pain. However, the relief of acute moderate to severe pain usually requires opioid agents. Considering the side effects of systemic drugs and the restrictions on the use of analgesics, especially opioids, regional blocks of pain as part of a multimodal analgesic strategy can be helpful. Conclusion: This study was designed to investigate and identify the disadvantages and advantages of using each drug to be able to make the right choices in different clinical situations for patients while paying attention to the limitations of the use of these analgesic drugs.
- 1 October 2018
- Vol. 2 (4) , e45
Open AccessPain Management in the Emergency Department: a Review Article on Options and Methods
Context: The aim of this review is to recognizing different methods of analgesia for emergency medicine physicians (EMPs) allows them to have various pain relief methods to reduce pain and to be able to use it according to the patient's condition and to improve the quality of their services. Evidence acquisition: In this review article, the search engines and scientific databases of Google Scholar, Science Direct, PubMed, Medline, Scopus, and Cochrane for emergency pain management methods were reviewed. Among the findings, high quality articles were eventually selected from 2000 to 2018, and after reviewing them, we have conducted a comprehensive comparison of the usual methods of pain control in the emergency department (ED). Results: For better understanding, the results are reported in to separate subheadings including "Parenteral agents" and "Regional blocks". Non-opioids analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are commonly used in the treatment of acute pain. However, the relief of acute moderate to severe pain usually requires opioid agents. Considering the side effects of systemic drugs and the restrictions on the use of analgesics, especially opioids, regional blocks of pain as part of a multimodal analgesic strategy can be helpful. Conclusion: This study was designed to investigate and identify the disadvantages and advantages of using each drug to be able to make the right choices in different clinical situations for patients while paying attention to the limitations of the use of these analgesic drugs.
- 22 August 2018
- Published by SAGE Publications in American Journal of Alzheimer's Disease and Other Dementias®
- Vol. 33 (8) , 541-547
Comparison of Blood Lead Levels in Patients With Alzheimer’s Disease and Healthy People
It is argued that breakdown of β-amyloid in the brain causes deposition of senescent plaques and therefore Alzheimer’s disease (AD). One of the influential factors for increasing level of this protein is exposure to lead. Our aim was to compare blood lead levels (BLLs) between patients with AD and healthy controls. This case–control study was performed on all patients with cognitive impairment who were referred to the Neurological Clinic of Birjand in 2016 to 2017. Patients were referred to the laboratory for measurement of their serum levels of lead. The controls and patients were matched by age and sex. In the AD case group, the average BLL was 22.22 ± 28.57 μg/dL. Mann-Whitney U test showed that BLLs were significantly higher in the patients than in the controls. The unadjusted odds ratio for BLL among the patients was 1.05 (95% confidence interval: 1.01-1.09; P = .01) compared to the controls. In the present study, BLL was associated with AD.
- 22 August 2018
- Published by SAGE Publications in American Journal of Alzheimer's Disease and Other Dementias®
- Vol. 33 (8) , 541-547
Comparison of Blood Lead Levels in Patients With Alzheimer’s Disease and Healthy People
It is argued that breakdown of β-amyloid in the brain causes deposition of senescent plaques and therefore Alzheimer’s disease (AD). One of the influential factors for increasing level of this protein is exposure to lead. Our aim was to compare blood lead levels (BLLs) between patients with AD and healthy controls. This case–control study was performed on all patients with cognitive impairment who were referred to the Neurological Clinic of Birjand in 2016 to 2017. Patients were referred to the laboratory for measurement of their serum levels of lead. The controls and patients were matched by age and sex. In the AD case group, the average BLL was 22.22 ± 28.57 μg/dL. Mann-Whitney U test showed that BLLs were significantly higher in the patients than in the controls. The unadjusted odds ratio for BLL among the patients was 1.05 (95% confidence interval: 1.01-1.09; P = .01) compared to the controls. In the present study, BLL was associated with AD.